Takeaways: Roche Canada’s completion of pCPA negotiations for Perjeta (pertuzumab) in the neoadjuvant setting (with trastuzumab + chemotherapy) for HER2‑positive, locally advanced, inflammatory...
Takeaways: The decision should expand use of Keytruda plus enfortumab vedotin in the perioperative setting by giving oncologists a data-backed option that improves event-free...
